The University of Chicago Header Logo

Mary Rinella

TitleProfessor
InstitutionUniversity of Chicago
DepartmentMedicine-Gastroenterology
AddressChicago IL 60637
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Israelsen M, Rinella ME, Krag A. Validating the new nomenclature of steatotic liver disease in patients with excessive alcohol intake - Authors' reply. Lancet Gastroenterol Hepatol. 2024 May; 9(5):409-410. PMID: 38604197.
      Citations:    
    2. Lazarus JV, Newsome PN, Rinella ME. Reply: NAFLD - there ain't no such thing as a free lunch. Hepatology. 2024 Mar 13. PMID: 38478768.
      Citations:    Fields:    
    3. Krag A, Rinella ME. Steatotic liver disease: a new name to reflect the combined role of alcohol and metabolic dysfunction. Nat Med. 2024 Mar 08. PMID: 38459182.
      Citations:    Fields:    
    4. Harrison SA, Bedossa P, Guy CD, Schattenberg JM, Loomba R, Taub R, Labriola D, Moussa SE, Neff GW, Rinella ME, Anstee QM, Abdelmalek MF, Younossi Z, Baum SJ, Francque S, Charlton MR, Newsome PN, Lanthier N, Schiefke I, Mangia A, Pericàs JM, Patil R, Sanyal AJ, Noureddin M, Bansal MB, Alkhouri N, Castera L, Rudraraju M, Ratziu V, MAESTRO-NASH Investigators. A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis. N Engl J Med. 2024 02 08; 390(6):497-509. PMID: 38324483.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    5. Hagström H, Adams LA, Allen AM, Byrne CD, Chang Y, Duseja A, Grønbæk H, Ismail MH, Jepsen P, Kanwal F, Kramer J, Loomba R, Mark HE, Newsome PN, Rinella ME, Rowe IA, Ryu S, Sanyal A, Schattenberg JM, Serper M, Sheron N, Simon TG, Spearman CW, Tapper EB, Villota-Rivas M, Wild SH, Wong VW, Yilmaz Y, Zelber-Sagi S, Åberg F, Lazarus JV. The future of International Classification of Diseases coding in steatotic liver disease: An expert panel Delphi consensus statement. Hepatol Commun. 2024 Feb 01; 8(2). PMID: 38315102; PMCID: PMC10843430.
      Citations:    Fields:    Translation:Humans
    6. Israelsen M, Torp N, Johansen S, Hansen CD, Hansen ED, Thorhauge K, Hansen JK, Villesen I, Bech K, Wernberg C, Andersen P, Lindvig KP, Tsochatzis EA, Thiele M, Rinella ME, Krag A, GALAXY consortium. Validation of the new nomenclature of steatotic liver disease in patients with a history of excessive alcohol intake: an analysis of data from a prospective cohort study. Lancet Gastroenterol Hepatol. 2024 Mar; 9(3):218-228. PMID: 38218202.
      Citations:    Fields:    Translation:Humans
    7. Abeysekera KWM, Valenti L, Younossi Z, Dillon JF, Allen AM, Nourredin M, Rinella ME, Tacke F, Francque S, Ginès P, Thiele M, Newsome PN, Guha IN, Eslam M, Schattenberg JM, Alqahtani SA, Arrese M, Berzigotti A, Holleboom AG, Caussy C, Cusi K, Roden M, Hagström H, Wong VW, Mallet V, Castera L, Lazarus JV, Tsochatzis EA. Implementation of a liver health check in people with type 2 diabetes. Lancet Gastroenterol Hepatol. 2024 Jan; 9(1):83-91. PMID: 38070521.
      Citations: 1     Fields:    Translation:Humans
    8. Sanyal AJ, Loomba R, Anstee QM, Ratziu V, Kowdley KV, Rinella ME, Harrison SA, Resnick MB, Capozza T, Sawhney S, Shelat N, Younossi ZM. Utility of pathologist panels for achieving consensus in NASH histologic scoring in clinical trials: Data from a phase 3 study. Hepatol Commun. 2024 Jan 01; 8(1). PMID: 38126958; PMCID: PMC10749704.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    9. Rinella ME, Castro Narro GE, Krag A, Terrault N, Newsome PN. Reply: 'From NAFLD to MASLD: Promise and pitfalls of a new definition' †. Hepatology. 2024 Feb 01; 79(2):E16-E17. PMID: 38112434.
      Citations: 5     Fields:    Translation:Humans
    10. Abdelmalek MF, Rinella ME. Steatotic liver disease, a useful construct in primary care that doesn't upset the apple cart. Hepatology. 2023 Dec 15. PMID: 38100309.
      Citations:    Fields:    
    11. Rinella ME, Sookoian S. From NAFLD to MASLD: updated naming and diagnosis criteria for fatty liver disease. J Lipid Res. 2024 Jan; 65(1):100485. PMID: 38103785; PMCID: PMC10824973.
      Citations:    Fields:    Translation:Humans
    12. Muthiah M, Bhat M, Watt KD, Siddiqui MS, Satapathy SK, Patidar KR, Brandman D, Rinella M. Defining an approach for therapeutic strategies in metabolic dysfunction-associated steatotic liver disease after liver transplantation. Hepatology. 2023 Dec 13. PMID: 38088872.
      Citations:    Fields:    
    13. Nadolsky K, Cryer DR, Articolo A, Fisher T, Schneider J, Rinella M. Nonalcoholic steatohepatitis diagnosis and treatment from the perspective of patients and primary care physicians: a cross-sectional survey. Ann Med. 2023 12; 55(1):2211349. PMID: 37171239; PMCID: PMC10184582.
      Citations: 1     Fields:    Translation:Humans
    14. Newsome PN, Francque SM, Kanwal F, Lazarus JV, Terrault NA, Rinella ME. Reply: A multi-society Delphi consensus statement on new fatty liver disease nomenclature. Hepatology. 2024 Mar 01; 79(3):E93-E94. PMID: 37983810.
      Citations: 58     Fields:    Translation:Humans
    15. Fornaresio L, Racila A, Golabi P, Global NASH Council, Younossi ZM, Alqahtani SA, Alswat K, Yilmaz Y, Keklikkiran C, Funuyet-Salas J, Romero-Gómez M, Fan JG, Zheng MH, El-Kassas M, Castera L, Liu CJ, Wai-Sun Wong V, Zelber-Sagi S, Allen AM, Lam B, Treeprasertsuk S, Hameed S, Takahashi H, Kawaguchi T, Schattenberg JM, Duseja A, Newsome PN, Francque S, Spearman CW, Castellanos Fernández MI, Burra P, Roberts SK, Chan WK, Arrese M, Silva M, Rinella M, Singal AK, Gordon S, Fuchs M, Alkhouri N, Cusi K, Loomba R, Ranagan J, Eskridge W, Kautz A, Ong JP, Kugelmas M, Eguchi Y, Diago M, Yu ML, Gerber L, Nader F, Henry L, Stepanova M, Carrieri P, Lazarus JV. Global survey of stigma among physicians and patients with nonalcoholic fatty liver disease. J Hepatol. 2024 Mar; 80(3):419-430. PMID: 37984709.
      Citations: 13     Fields:    Translation:Humans
    16. Kanwal F, Neuschwander-Tetri BA, Loomba R, Rinella ME. Metabolic dysfunction-associated steatotic liver disease: Update and impact of new nomenclature on the American Association for the Study of Liver Diseases practice guidance on nonalcoholic fatty liver disease. Hepatology. 2023 Nov 09. PMID: 38445559.
      Citations: 1     Fields:    
    17. Rinella ME. Examining the Nomenclature Change From NAFLD and NASH to MASLD and MASH. Gastroenterol Hepatol (N Y). 2023 Nov; 19(11):697-699. PMID: 38405223; PMCID: PMC10882866.
      Citations:    
    18. Odenwald MA, Lin H, Lehmann C, Dylla NP, Cole CG, Mostad JD, Pappas TE, Ramaswamy R, Moran A, Hutchison AL, Stutz MR, Dela Cruz M, Adler E, Boissiere J, Khalid M, Cantoral J, Haro F, Oliveira RA, Waligurski E, Cotter TG, Light SH, Beavis KG, Sundararajan A, Sidebottom AM, Reddy KG, Paul S, Pillai A, Te HS, Rinella ME, Charlton MR, Pamer EG, Aronsohn AI. Bifidobacteria metabolize lactulose to optimize gut metabolites and prevent systemic infection in patients with liver disease. Nat Microbiol. 2023 Nov; 8(11):2033-2049. PMID: 37845315.
      Citations: 1     Fields:    Translation:HumansAnimals
    19. Krag A, Rinella ME. Pioneering the path to NASH biomarker approval. Nat Med. 2023 10; 29(10):2416-2417. PMID: 37679432.
      Citations:    Fields:    Translation:Humans
    20. Sinclair M, Rinella ME, Lieu HD, Kowdley KV, Goodman ZD, Alkhouri N, Lawitz E, Abdelmalek MF, Wong VW, Younes ZH, Sheikh AM, Brannan D, Freilich B, Membreno F, Melchor-Khan L, Sanyal AJ, Ling L, Harrison SA, Ratziu V. A randomized, double-blind, placebo-controlled trial of aldafermin in patients with NASH and compensated cirrhosis. Hepatology. 2024 Mar 01; 79(3):674-689. PMID: 37732990; PMCID: PMC10871650.
      Citations: 5     Fields:    Translation:Humans
    21. Rinella ME. Pegozafermin for NASH - A Sprint to Start a Marathon. N Engl J Med. 2023 Sep 14; 389(11):1044-1046. PMID: 37703559.
      Citations:    Fields:    Translation:Humans
    22. Newsome P, Rinella ME, Lazarus JV, Terrault N. Reply: NAFLD, MAFLD, or MASLD? Cut the Gordian knot with "Ludwig disease". Hepatology. 2024 Jan 01; 79(1):E5-E6. PMID: 37651218.
      Citations: 1     Fields:    Translation:Humans
    23. Krag A, Buti M, Lazarus JV, Allen AM, Bowman J, Burra P, Donnini G, Duseja A, El-Sayed MH, Gastaldelli A, Hainsworth B, Karlsen TH, Kessler M, Korenjak M, Mark HE, Mann JP, Miller V, Pessoa MG, Piñeiro D, Sarin SK, Singh SP, Rinella ME, Willemse J, Younossi ZM, Francque SM. Uniting to defeat steatotic liver disease: A global mission to promote healthy livers and healthy lives. J Hepatol. 2023 Nov; 79(5):1076-1078. PMID: 37634993.
      Citations: 7     Fields:    
    24. Arrese M, Kautz A, Silva M, Zelber-Sagi S, Lazarus JV, Mark HE, Allen AM, Arab JP, Carrieri P, Noureddin M, Alazawi W, Alkhouri N, Alqahtani SA, Anstee QM, Bataller R, Berg T, Brennan PN, Burra P, Castro-Narro GE, Cortez-Pinto H, Cusi K, Duseja A, Francque SM, Gastaldelli A, Hagström H, Huang TTK, Ivancovsky Wajcman D, Kopka CJ, Krag A, Newsome PN, Rinella ME, Romero D, Sarin SK, Spearman CW, Terrault NA, Tsochatzis EA, Valenti L, Villota-Rivas M, Schattenberg JM, Wong VW, Younossi ZM, Dedes N, on behalf of the Healthy Livers, H. A global action agenda for turning the tide on fatty liver disease. Hepatology. 2024 Feb 01; 79(2):502-523. PMID: 37540183; PMCID: PMC10789386.
      Citations: 2     Fields:    Translation:Humans
    25. Sanyal AJ, Ratziu V, Loomba R, Anstee QM, Kowdley KV, Rinella ME, Sheikh MY, Trotter JF, Knapple W, Lawitz EJ, Abdelmalek MF, Newsome PN, Boursier J, Mathurin P, Dufour JF, Berrey MM, Shiff SJ, Sawhney S, Capozza T, Leyva R, Harrison SA, Younossi ZM. Results from a new efficacy and safety analysis of the REGENERATE trial of obeticholic acid for treatment of pre-cirrhotic fibrosis due to non-alcoholic steatohepatitis. J Hepatol. 2023 Nov; 79(5):1110-1120. PMID: 37517454.
      Citations: 5     Fields:    
    26. Rinella ME, Lazarus JV, Ratziu V, Francque SM, Sanyal AJ, Kanwal F, Romero D, Abdelmalek MF, Anstee QM, Arab JP, Bataller R, Beuers U, Boursier J, Bugianesi E, Castro Narro GE, Cortez-Pinto H, Cusi K, El-Kassas M, Klein S, Eskridge W, Fan J, Gawrieh S, Guy CD, Kim SU, Korenjak M, Lacaille F, Mitchell-Thain R, Morgan TR, Roden M, Silva M, Singh SP, Spearman CW, Tiniakos D, Valenti L, Wong VW, Yilmaz Y, Younossi Z, Hobbs A, Villota-Rivas M, Newsome PN, NAFLD Nomenclature consensus group, Arrese M, Byrne CD, Chowdhury A, Cryer DR, Harrison SA, Koot BG, Kowdley KV, Loomba R, Powell EE, Romero-Gómez M, Sookoian SC, Vos MB, Xanthakos S. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology. 2023 Dec 01; 78(6):1966-1986. PMID: 37363821; PMCID: PMC10653297.
      Citations: 74     Fields:    Translation:Humans
    27. Rinella ME, Lazarus JV, Ratziu V, Francque SM, Sanyal AJ, Kanwal F, Romero D, Abdelmalek MF, Anstee QM, Bataller R, Boursier J, Bugianesi E, Castro Narro GE, Cortez-Pinto H, Cusi K, El-Kassas M, Klein S, Eskridge W, Fan J, Gawrieh S, Guy CD, Kim SU, Korenjak M, Lacaille F, Mitchell-Thain R, Morgan TR, Roden M, Silva M, Singh SP, Spearman CW, Tiniakos D, Valenti L, Yilmaz Y, Hobbs A, Villota-Rivas M, Newsome PN, NAFLD Nomenclature consensus group, Arab JP, Arrese M, Beuers U, Byrne CD, Chowdhury A, Cryer DR, Harrison SA, Koot BG, Kowdley KV, Loomba R, Powell EE, Romero-Gómez M, Sookoian SC, Vos MB, Wong VW, Xanthakos S, Younossi Z. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol. 2023 12; 79(6):1542-1556. PMID: 37364790.
      Citations: 111     Fields:    Translation:Humans
    28. Rinella ME, Lazarus JV, Ratziu V, Francque SM, Sanyal AJ, Kanwal F, Romero D, Abdelmalek MF, Anstee QM, Bataller R, Beuers U, Boursier J, Bugianesi E, Narro GEC, Cortez-Pinto H, Cusi K, El-Kassas M, Klein S, Eskridge W, Fan J, Gawrieh S, Guy CD, Kim SU, Korenjak M, Lacaille F, Mitchell-Thain R, Morgan TR, Roden M, Silva M, Singh SP, Spearman CW, Tiniakos D, Valenti L, Wong VW, Yilmaz Y, Hobbs A, Villota-Rivas M, NAFLD Nomenclature consensus group, Byrne CD, Arab JP, Arrese M, Chowdhury A, Cryer DR, Harrison SA, Koot BG, Kowdley KV, Loomba R, Powell EE, Romero-Gómez M, Sookoian SC, Vos MB, Xanthakos S, Younossi Z, Newsome PN. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Ann Hepatol. 2024 Jan-Feb; 29(1):101133. PMID: 37364816.
      Citations: 77     Fields:    Translation:Humans
    29. Lazarus JV, Mark HE, Allen AM, Arab JP, Carrieri P, Noureddin M, Alazawi W, Alkhouri N, Alqahtani SA, Arrese M, Bataller R, Berg T, Brennan PN, Burra P, Castro-Narro GE, Cortez-Pinto H, Cusi K, Dedes N, Duseja A, Francque SM, Hagström H, Huang TT, Wajcman DI, Kautz A, Kopka CJ, Krag A, Miller V, Newsome PN, Rinella ME, Romero D, Sarin SK, Silva M, Spearman CW, Tsochatzis EA, Valenti L, Villota-Rivas M, Zelber-Sagi S, Schattenberg JM, Wong VW, Younossi ZM, Healthy Livers, Healthy Lives Collaborators. A global research priority agenda to advance public health responses to fatty liver disease. J Hepatol. 2023 09; 79(3):618-634. PMID: 37353401.
      Citations: 10     Fields:    Translation:HumansPHPublic Health
    30. Lim WH, Ng CH, Xiao J, Yong JN, Zeng RW, Cho E, Tay P, Ang CZ, Koh JH, Teng M, Syn N, Kow A, Huang DQ, Tan EX, Muthiah M, Tan D, Tseng M, Rinella ME, Sanyal A, Siddiqui MS. Natural history of NASH cirrhosis in liver transplant waitlist registrants. J Hepatol. 2023 10; 79(4):1015-1024. PMID: 37307997.
      Citations: 2     Fields:    Translation:Humans
    31. Rinella ME, Terrault N, Neuschwander-Tetri B, Loomba R. Reply: People living with HIV and NAFLD and updated guidance on NAFLD screening. Hepatology. 2023 11 01; 78(5):E91-E92. PMID: 37203291.
      Citations:    Fields:    Translation:Humans
    32. Rinella ME, Terrault N, Neuschwander-Tetri B, Loomba R, Abdelmalek M. Reply: ELF in the risk stratification of NAFLD-Are the ELF thresholds suggested by the AASLD guidelines appropriate? Hepatology. 2023 Dec 01; 78(6):E103-E104. PMID: 37199166.
      Citations:    Fields:    Translation:Humans
    33. Gadano AC, Martic M, Kochuparampil J, Naoumov NV, Anstee QM, Lucas KJ, Francque S, Abdelmalek MF, Sanyal AJ, Ratziu V, Rinella M, Charlton M, Loomba R, Mena E, Schattenberg JM, Noureddin M, Lazas D, Goh GBB, Sarin SK, Yilmaz Y, Stringer R, Chen L, Rodriguez-Araujo G, Chng E, Brass C, Pedrosa MC. Tropifexor plus cenicriviroc combination versus monotherapy in nonalcoholic steatohepatitis: Results from the phase 2b TANDEM study. Hepatology. 2023 10 01; 78(4):1223-1239. PMID: 37162151; PMCID: PMC10521801.
      Citations: 4     Fields:    Translation:Humans
    34. Odenwald MA, Rinella ME. Recurrent NAFLD post-LT: Sisyphus' boulder or Proteus' parable? Liver Transpl. 2023 09 01; 29(9):917-918. PMID: 37071070.
      Citations:    Fields:    Translation:Humans
    35. Rinella ME, Siddiqui MS, Loomba R, Neuschwander-Tetri BA, Abdelmalek MF, Caldwell S, Barb D, Kleiner DE. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology. 2023 05 01; 77(5):1797-1835. PMID: 36727674; PMCID: PMC10735173.
      Citations: 175     Fields:    Translation:Humans
    36. Ibrahim MK, Simon TG, Rinella ME. Extrahepatic Outcomes of Nonalcoholic Fatty Liver Disease: Nonhepatocellular Cancers. Clin Liver Dis. 2023 05; 27(2):251-273. PMID: 37024206.
      Citations: 1     Fields:    Translation:Humans
    37. Bataller R, Cusi K, Dillon JF, Mateo M, Rinella ME, Zelber-Sagi S, Iruzubieta P, Arias-Loste MT, Arrese M, Calleja JL, Castro-Narro G, Martínez-Chantar ML, Pérez A, Romero-Gómez M, Schattenberg JM, Crespo J, Lazarus JV. Research Priorities for Precision Medicine in NAFLD. Clin Liver Dis. 2023 05; 27(2):535-551. PMID: 37024222.
      Citations: 3     Fields:    Translation:Humans
    38. Heinz S, Balp MM, Brass C, Pedrosa M, Cai J, Hoad R, Sayadian AC, Rinella M, Geier A, Ratziu V. The Cost of Diagnosing and Managing Non-alcoholic Steatohepatitis in Europe and the United States. J Gastrointestin Liver Dis. 2022 09 15; 31(3):317-322. PMID: 36004416.
      Citations:    Fields:    Translation:Humans
    39. Rinella M, Cryer DR, Articolo A, Fisher T, Schneider J, Nadolsky K. Nonalcoholic steatohepatitis medical patient journey from the perspective of hepatologists, gastroenterologists and patients: a cross-sectional survey. BMC Gastroenterol. 2022 Jul 10; 22(1):335. PMID: 35811319; PMCID: PMC9272554.
      Citations: 3     Fields:    Translation:Humans
    40. Cusi K, Isaacs S, Barb D, Basu R, Caprio S, Garvey WT, Kashyap S, Mechanick JI, Mouzaki M, Nadolsky K, Rinella ME, Vos MB, Younossi Z. American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings: Co-Sponsored by the American Association for the Study of Liver Diseases (AASLD). Endocr Pract. 2022 May; 28(5):528-562. PMID: 35569886.
      Citations: 141     Fields:    Translation:Humans
    41. Harrison SA, Abdelmalek MF, Neff G, Gunn N, Guy CD, Alkhouri N, Bashir MR, Freilich B, Kohli A, Khazanchi A, Sheikh MY, Leibowitz M, Rinella ME, Siddiqui MS, Kipnes M, Moussa SE, Younes ZH, Bansal M, Baum SJ, Borg B, Ruane PJ, Thuluvath PJ, Gottwald M, Khan M, Chen C, Melchor-Khan L, Chang W, DePaoli AM, Ling L, Lieu HD. Aldafermin in patients with non-alcoholic steatohepatitis (ALPINE 2/3): a randomised, double-blind, placebo-controlled, phase 2b trial. Lancet Gastroenterol Hepatol. 2022 07; 7(7):603-616. PMID: 35325622.
      Citations: 21     Fields:    Translation:HumansCTClinical Trials
    42. Rinella ME, Satapathy SK, Brandman D, Smith C, Elwir S, Xia J, Gibson M, Figueredo C, Angirekula M, Vanatta JM, Sarwar R, Jiang Y, Gregory D, Agostini T, Ko J, Podila P, Gallo G, Watt KD, Siddiqui MS. Factors Impacting Survival in Those Transplanted for NASH Cirrhosis: Data From the NailNASH Consortium. Clin Gastroenterol Hepatol. 2023 02; 21(2):445-455.e2. PMID: 35189388.
      Citations: 4     Fields:    Translation:Humans
    43. Mark HE, Rinella ME, Colombo M, Lazarus JV. Editorial: global liver fat accumulation and global health-towards a sustainable development goal. Authors' reply. Aliment Pharmacol Ther. 2022 02; 55(4):489-490. PMID: 35092059.
      Citations:    Fields:    Translation:Humans
    44. Brunt EM, Clouston AD, Goodman Z, Guy C, Kleiner DE, Lackner C, Tiniakos DG, Wee A, Yeh M, Leow WQ, Chng E, Ren Y, Boon Bee GG, Powell EE, Rinella M, Sanyal AJ, Neuschwander-Tetri B, Younossi Z, Charlton M, Harrison SA, Tai D, Anstee QM, Ratziu V. Complexity of ballooned hepatocyte feature recognition: Defining a training atlas for artificial intelligence-based imaging in NAFLD. J Hepatol. 2022 05; 76(5):1030-1041. PMID: 35090960; PMCID: PMC10544770.
      Citations: 29     Fields:    Translation:HumansCells
    45. Lazarus JV, Mark HE, Colombo M, Demaio S, Dillon JF, George J, Hocking S, Lee N, Nieuwenhuijsen MJ, Rinella ME, Romero-Gomez M, Soriano JB, Tacke F, Tsochatzis EA, Valenti L, Zelber-Sagi S, Ashworth Dirac M, Huang TT, Hagström H, Schattenberg JM. A sustainable development goal framework to guide multisectoral action on NAFLD through a societal approach. Aliment Pharmacol Ther. 2022 01; 55(2):234-243. PMID: 34866201.
      Citations: 2     Fields:    Translation:HumansPHPublic Health
    46. Saiman Y, Duarte-Rojo A, Rinella ME. Fatty Liver Disease: Diagnosis and Stratification. Annu Rev Med. 2022 01 27; 73:529-544. PMID: 34809436; PMCID: PMC10074159.
      Citations: 5     Fields:    Translation:Humans
    47. Rinella ME, Dufour JF, Anstee QM, Goodman Z, Younossi Z, Harrison SA, Loomba R, Sanyal AJ, Bonacci M, Trylesinski A, Natha M, Shringarpure R, Granston T, Venugopal A, Ratziu V. Non-invasive evaluation of response to obeticholic acid in patients with NASH: Results from the REGENERATE study. J Hepatol. 2022 03; 76(3):536-548. PMID: 34793868.
      Citations: 27     Fields:    Translation:Humans
    48. Mowry CJ, Alonso C, Iruarrizaga-Lejarreta M, Ortiz P, Levitsky J, Rinella M. Utility of Metabolomic Biomarkers to Identify Nonalcoholic Fatty Liver Disease in Liver Transplant Recipients. Transplant Direct. 2021 Dec; 7(12):e784. PMID: 34778544; PMCID: PMC8580200.
      Citations: 3     
    49. Rinella ME, Neuschwander-Tetri BA, Lawitz E, Denham D, Kayali Z, Sheikh A, Kowdley KV, Desta T, Elkhashab M, DeGrauw J, Goodwin B, Ahmad A, Adda N, Ratziu V. EDP-305 in patients with NASH: A phase II double-blind placebo-controlled dose-ranging study. J Hepatol. 2022 03; 76(3):506-517. PMID: 34740705.
      Citations: 23     Fields:    Translation:Humans
    50. Mark HE, Anstee QM, Arab JP, Batterham RL, Cusi K, Dirac MA, Francque S, George J, Huang TT, Ismail MH, Sarin SK, Loomba R, Miller V, Newsome PN, Ninburg M, Ocama P, Rinella M, Romero D, Tsochatzis EA, Wong VW, Yilmaz Y, Younossi ZM, Zelber-Sagi S, NAFLD Consensus Consortium, Lazarus JV, Castera L, Cortez-Pinto H, Crespo J, Hagström H, Kautz A, Ratziu V, Romero-Gómez M, Schattenberg JM, Valenti L. Advancing the global public health agenda for NAFLD: a consensus statement. Nat Rev Gastroenterol Hepatol. 2022 01; 19(1):60-78. PMID: 34707258.
      Citations: 161     Fields:    Translation:Humans
    51. Kanwal F, Shubrook JH, Younossi Z, Natarajan Y, Bugianesi E, Rinella ME, Harrison SA, Mantzoros C, Pfotenhauer K, Klein S, Eckel RH, Kruger D, El-Serag H, Cusi K. Preparing for the NASH epidemic: A call to action. Obesity (Silver Spring). 2021 09; 29(9):1401-1412. PMID: 34365735.
      Citations: 3     Fields:    Translation:HumansPHPublic Health
    52. Kanwal F, Shubrook JH, Younossi Z, Natarajan Y, Bugianesi E, Rinella ME, Harrison SA, Mantzoros C, Pfotenhauer K, Klein S, Eckel RH, Kruger D, El-Serag H, Cusi K. Preparing for the NASH Epidemic: A Call to Action. Diabetes Care. 2021 09; 44(9):2162-2172. PMID: 34312182.
      Citations: 13     Fields:    Translation:HumansPHPublic Health
    53. Kanwal F, Shubrook JH, Younossi Z, Natarajan Y, Bugianesi E, Rinella ME, Harrison SA, Mantzoros C, Pfotenhauer K, Klein S, Eckel RH, Kruger D, El-Serag H, Cusi K. Preparing for the NASH Epidemic: A Call to Action. Gastroenterology. 2021 09; 161(3):1030-1042.e8. PMID: 34416976.
      Citations: 30     Fields:    Translation:HumansPHPublic Health
    54. Loomba R, Mohseni R, Lucas KJ, Gutierrez JA, Perry RG, Trotter JF, Rahimi RS, Harrison SA, Ajmera V, Wayne JD, O'Farrell M, McCulloch W, Grimmer K, Rinella M, Wai-Sun Wong V, Gores GJ, Neuschwander-Tetri BA, Kemble G, Ratziu V. TVB-2640 (FASN Inhibitor) for the Treatment of Nonalcoholic Steatohepatitis: FASCINATE-1, a Randomized, Placebo-Controlled Phase 2a Trial. Gastroenterology. 2021 11; 161(5):1475-1486. PMID: 34310978.
      Citations: 51     Fields:    Translation:HumansCellsCTClinical Trials
    55. Kanwal F, Shubrook JH, Younossi Z, Natarajan Y, Bugianesi E, Rinella ME, Harrison SA, Mantzoros C, Pfotenhauer K, Klein S, Eckel RH, Kruger D, El-Serag H, Cusi K. Preparing for the NASH epidemic: A call to action. Metabolism. 2021 09; 122:154822. PMID: 34289945.
      Citations: 9     Fields:    Translation:HumansPHPublic Health
    56. Younossi ZM, Stepanova M, Nader F, Loomba R, Anstee QM, Harrison S, Sanyal AJ, Barritt AS, Noureddin M, Bonacci M, Cawkwell G, Wong B, Rinella M, RandomizEd Global Phase 3 Study to Evaluate the Impact on NASH with FibRosis of Obeticholic Acid Tre, Ratziu V, Schattenberg JM. Obeticholic Acid Impact on Quality of Life in Patients With Nonalcoholic Steatohepatitis: REGENERATE 18-Month Interim Analysis. Clin Gastroenterol Hepatol. 2022 09; 20(9):2050-2058.e12. PMID: 34274514.
      Citations: 18     Fields:    Translation:HumansCTClinical Trials
    57. Brunt EM, Kleiner DE, Carpenter DH, Rinella M, Harrison SA, Loomba R, Younossi Z, Neuschwander-Tetri BA, Sanyal AJ, American Association for the Study of Liver Diseases NASH Task Force. NAFLD: Reporting Histologic Findings in Clinical Practice. Hepatology. 2021 05; 73(5):2028-2038. PMID: 33111374.
      Citations: 41     Fields:    Translation:Humans
    58. Powell EE, Wong VW, Rinella M. Non-alcoholic fatty liver disease. Lancet. 2021 06 05; 397(10290):2212-2224. PMID: 33894145.
      Citations: 532     Fields:    Translation:Humans
    59. Younossi ZM, Rinella ME, Sanyal AJ, Harrison SA, Brunt EM, Goodman Z, Cohen DE, Loomba R. From NAFLD to MAFLD: Implications of a Premature Change in Terminology. Hepatology. 2021 03; 73(3):1194-1198. PMID: 32544255.
      Citations: 131     Fields:    Translation:Humans
    60. Shroff H, Rinella ME. Thanks to CLD for Small Favors: Reduced CVD Risk in Patients Awaiting Liver Transplantation. Dig Dis Sci. 2021 01; 66(1):7-9. PMID: 32472257.
      Citations: 1     Fields:    Translation:Humans
    61. Singh SP, Anirvan P, Reddy KR, Conjeevaram HS, Marchesini G, Rinella ME, Madan K, Petroni ML, Al-Mahtab M, Caldwell SH, Aithal GP, Hamid SS, Farrell GC, Satapathy SK, Duseja A, Acharya SK, Dassanayake AS, Goh KL. Non-alcoholic fatty liver disease: Not time for an obituary just yet! J Hepatol. 2021 04; 74(4):972-974. PMID: 33340575.
      Citations: 12     Fields:    Translation:Humans
    62. Lee BP, Im GY, Rice JP, Lazar A, Weinberg E, Han H, Maddur H, Ghobrial RM, Therapondos G, Hsu C, Fix OK, Eswaran S, Shetty K, Chhatwal J, Dalgic OO, Jakhete N, Mobley C, Victor DW, Mehta N, Dinges L, Rinella M, Schiano TD, Lucey MR, Terrault N. Patterns of Alcohol Use After Early Liver Transplantation for Alcoholic Hepatitis. Clin Gastroenterol Hepatol. 2022 02; 20(2):409-418.e5. PMID: 33279780.
      Citations: 9     Fields:    Translation:Humans
    63. Rinella M, Beuers U, Loomba R, Anstee QM, Harrison S, Francque S, Sanyal A, Newsome PN, Younossi Z, Ratziu V. The times they are a-changin' (for NAFLD as well). J Hepatol. 2020 12; 73(6):1307-1309. PMID: 32890593.
      Citations: 18     Fields:    Translation:Humans
    64. Noureddin M, Jones C, Alkhouri N, Gomez EV, Dieterich DT, Rinella ME, NASHNET. Screening for Nonalcoholic Fatty Liver Disease in Persons with Type 2 Diabetes in the United States Is Cost-effective: A Comprehensive Cost-Utility Analysis. Gastroenterology. 2020 11; 159(5):1985-1987.e4. PMID: 32763241.
      Citations: 40     Fields:    Translation:Humans
    65. Rinella ME, Balp MM, McKenna SJ, Brass CA, Przybysz R, Cai J, Knight A, Gavaghan M, Howe T, Rosen D, Geier A, Ratziu V. Real-World Burden of Nonalcoholic Steatohepatitis. Clin Gastroenterol Hepatol. 2021 05; 19(5):1020-1029.e7. PMID: 32634622.
      Citations: 7     Fields:    Translation:Humans
    66. Patel K, Harrison SA, Elkhashab M, Trotter JF, Herring R, Rojter SE, Kayali Z, Wong VW, Greenbloom S, Jayakumar S, Shiffman ML, Freilich B, Lawitz EJ, Gane EJ, Harting E, Xu J, Billin AN, Chung C, Djedjos CS, Subramanian GM, Myers RP, Middleton MS, Rinella M, Noureddin M. Cilofexor, a Nonsteroidal FXR Agonist, in Patients With Noncirrhotic NASH: A Phase 2 Randomized Controlled Trial. Hepatology. 2020 07; 72(1):58-71. PMID: 32115759.
      Citations: 117     Fields:    Translation:HumansCTClinical Trials
    67. Younossi ZM, Corey KE, Alkhouri N, Noureddin M, Jacobson I, Lam B, Clement S, Basu R, Gordon SC, Ravendhra N, Puri P, Rinella M, Scudera P, Singal AK, Henry L, US Members of the Global Nash Council. Clinical assessment for high-risk patients with non-alcoholic fatty liver disease in primary care and diabetology practices. Aliment Pharmacol Ther. 2020 08; 52(3):513-526. PMID: 32598051.
      Citations: 23     Fields:    Translation:Humans
    68. Rinella ME, Noureddin M. STELLAR 3 and STELLAR 4: Lessons from the fall of Icarus. J Hepatol. 2020 07; 73(1):9-11. PMID: 32360996; PMCID: PMC7191297.
      Citations: 10     Fields:    Translation:Humans
    69. Cotter TG, Rinella M. Nonalcoholic Fatty Liver Disease 2020: The State of the Disease. Gastroenterology. 2020 05; 158(7):1851-1864. PMID: 32061595.
      Citations: 399     Fields:    Translation:HumansAnimals
    70. VanWagner LB, Wilcox JE, Ning H, Lewis CE, Carr JJ, Rinella ME, Shah SJ, Lima JAC, Lloyd-Jones DM. Longitudinal Association of Non-Alcoholic Fatty Liver Disease With Changes in Myocardial Structure and Function: The CARDIA Study. J Am Heart Assoc. 2020 02 18; 9(4):e014279. PMID: 32067588; PMCID: PMC7070184.
      Citations: 39     Fields:    Translation:Humans
    71. Younossi ZM, Loomba R, Rinella M, Anstee QM, Goodman Z, Geier A, Beckebaum S, Newsome PN, Sheridan D, Sheikh MY, Trotter J, Knapple W, Lawitz E, Abdelmalek MF, Kowdley KV, Montano-Loza AJ, Boursier J, Mathurin P, Bugianesi E, Mazzella G, Olveira A, Orr D, Gluud LL, Dufour JF, Shapiro D, Campagna J, Zaru L, MacConell L, Shringarpure R, Harrison S, Sanyal AJ, REGENERATE Study Investigators, Ratziu V, Bedossa P, Cortez-Pinto H, Graupera I. Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. Lancet. 2019 12 14; 394(10215):2184-2196. PMID: 31813633.
      Citations: 410     Fields:    Translation:HumansCTClinical Trials
    72. Chalasani N, Abdelmalek MF, Garcia-Tsao G, Vuppalanchi R, Alkhouri N, Rinella M, Noureddin M, Pyko M, Shiffman M, Sanyal A, Allgood A, Shlevin H, Horton R, Zomer E, Irish W, Goodman Z, Harrison SA, Traber PG, Belapectin (GR-MD-02) Study Investigators. Effects of Belapectin, an Inhibitor of Galectin-3, in Patients With Nonalcoholic Steatohepatitis With Cirrhosis and Portal Hypertension. Gastroenterology. 2020 04; 158(5):1334-1345.e5. PMID: 31812510.
      Citations: 115     Fields:    Translation:HumansCTClinical Trials
    73. Pedrosa M, Seyedkazemi S, Francque S, Sanyal A, Rinella M, Charlton M, Loomba R, Kochuparampil J, Fischer L, Vaidyanathan S, Anstee QM, Ratziu V. A randomized, double-blind, multicenter, phase 2b study to evaluate the safety and efficacy of a combination of tropifexor and cenicriviroc in patients with nonalcoholic steatohepatitis and liver fibrosis: Study design of the TANDEM trial. Contemp Clin Trials. 2020 01; 88:105889. PMID: 31731005.
      Citations: 44     Fields:    Translation:HumansCTClinical Trials
    74. Cheung A, Neuschwander-Tetri BA, Kleiner DE, Rinella M, Harrison S, Sanyal AJ, Loomba R, Jeannin Megnien S, Torstenson R, Miller V, Liver Forum Case Definitions Working Group, Schabel E, Ratziu V. Defining Improvement in Nonalcoholic Steatohepatitis for Treatment Trial Endpoints: Recommendations From the Liver Forum. Hepatology. 2019 11; 70(5):1841-1855. PMID: 31034092.
      Citations: 23     Fields:    Translation:Humans
    75. Cleveland ER, Ning H, Vos MB, Lewis CE, Rinella ME, Carr JJ, Lloyd-Jones DM, VanWagner LB. Low Awareness of Nonalcoholic Fatty Liver Disease in a Population-Based Cohort Sample: the CARDIA Study. J Gen Intern Med. 2019 12; 34(12):2772-2778. PMID: 31595464; PMCID: PMC6854130.
      Citations: 17     Fields:    Translation:HumansPHPublic Health
    76. Samji NS, Verma R, Keri KC, Singal AK, Ahmed A, Rinella M, Bernstein D, Abdelmalek MF, Satapathy SK. Liver Transplantation for Nonalcoholic Steatohepatitis: Pathophysiology of Recurrence and Clinical Challenges. Dig Dis Sci. 2019 12; 64(12):3413-3430. PMID: 31312990.
      Citations: 3     Fields:    Translation:Humans
    77. Rinella ME, Sanyal AJ, Anstee QM, participants of the AASLD/EASL Workshop, Tacke F. Report on the AASLD/EASL joint workshop on clinical trial endpoints in NAFLD. J Hepatol. 2019 10; 71(4):823-833. PMID: 31300231.
      Citations: 51     Fields:    Translation:Humans
    78. Rinella ME, Sanyal AJ, Anstee QM, participants of the AASLD/EASL Workshop, Tacke F. Report on the AASLD/EASL Joint Workshop on Clinical Trial Endpoints in NAFLD. Hepatology. 2019 10; 70(4):1424-1436. PMID: 31287572.
      Citations: 36     Fields:    Translation:HumansPHPublic Health
    79. Siddiqui MB, Patel S, Bhati C, Reichman T, Williams K, Driscoll C, Liptrap E, Rinella ME, Sterling RK, Siddiqui MS. Range of Normal Serum Aminotransferase Levels in Liver Transplant Recipients. Transplant Proc. 2019 Jul - Aug; 51(6):1895-1901. PMID: 31399173; PMCID: PMC7050287.
      Citations: 2     Fields:    Translation:HumansCells
    80. Sanyal AJ, Loomba R, Rinella M, Harrison S, Anstee QM, Goodman Z, MacConell L, Shringarpure R, Shah A, Younossi Z, Ratziu V, Bedossa P. REGENERATE: Design of a pivotal, randomised, phase 3 study evaluating the safety and efficacy of obeticholic acid in patients with fibrosis due to nonalcoholic steatohepatitis. Contemp Clin Trials. 2019 09; 84:105803. PMID: 31260793.
      Citations: 49     Fields:    Translation:HumansCTClinical Trials
    81. Sarkar M, VanWagner LB, Terry JG, Carr JJ, Rinella M, Schreiner PJ, Lewis CE, Terrault N, Coronary Artery Risk Development in Young Adults (CARDIA) Cohort. Sex Hormone-Binding Globulin Levels in Young Men Are Associated With Nonalcoholic Fatty Liver Disease in Midlife. Am J Gastroenterol. 2019 05; 114(5):758-763. PMID: 30730350; PMCID: PMC6599461.
      Citations: 8     Fields:    Translation:Humans
    82. Lee BP, Samur S, Dalgic OO, Bethea ED, Lucey MR, Weinberg E, Hsu C, Rinella ME, Im GY, Fix OK, Therapondos G, Han H, Victor DW, Voigt MD, Eswaran S, Terrault NA, Chhatwal J. Model to Calculate Harms and Benefits of Early vs Delayed Liver Transplantation for Patients With Alcohol-Associated Hepatitis. Gastroenterology. 2019 08; 157(2):472-480.e5. PMID: 30998988; PMCID: PMC6650344.
      Citations: 16     Fields:    Translation:Humans
    83. Mazumder N, Rinella M. Editorial: sarcopenia in liver transplantation-our weakest patients may need the strongest push. Aliment Pharmacol Ther. 2019 04; 49(8):1100-1101. PMID: 30920044; PMCID: PMC6483369.
      Citations: 1     Fields:    Translation:Humans
    84. Cheung A, Figueredo C, Rinella ME. Nonalcoholic Fatty Liver Disease: Identification and Management of High-Risk Patients. Am J Gastroenterol. 2019 04; 114(4):579-590. PMID: 30839326.
      Citations: 15     Fields:    Translation:Humans
    85. Zemel MB, Kolterman O, Rinella M, Vuppalanchi R, Flores O, Barritt AS, Siddiqui M, Chalasani N. Randomized Controlled Trial of a Leucine-Metformin-Sildenafil Combination (NS-0200) on Weight and Metabolic Parameters. Obesity (Silver Spring). 2019 01; 27(1):59-67. PMID: 30569637.
      Citations: 12     Fields:    Translation:HumansCTClinical Trials
    86. Whitsett M, Wilcox J, Yang A, Zhao L, Rinella M, VanWagner LB. Atrial fibrillation is highly prevalent yet undertreated in patients with biopsy-proven nonalcoholic steatohepatitis. Liver Int. 2019 05; 39(5):933-940. PMID: 30536602; PMCID: PMC6483865.
      Citations: 7     Fields:    Translation:Humans
    87. Rinella ME, Trotter JF, Abdelmalek MF, Paredes AH, Connelly MA, Jaros MJ, Ling L, Rossi SJ, DePaoli AM, Harrison SA. Rosuvastatin improves the FGF19 analogue NGM282-associated lipid changes in patients with non-alcoholic steatohepatitis. J Hepatol. 2019 04; 70(4):735-744. PMID: 30529590.
      Citations: 37     Fields:    Translation:HumansCTClinical Trials
    88. Stine JG, Wentworth BJ, Zimmet A, Rinella ME, Loomba R, Caldwell SH, Argo CK. Systematic review with meta-analysis: risk of hepatocellular carcinoma in non-alcoholic steatohepatitis without cirrhosis compared to other liver diseases. Aliment Pharmacol Ther. 2018 10; 48(7):696-703. PMID: 30136293; PMCID: PMC7495494.
      Citations: 114     Fields:    Translation:Humans
    89. Friedman SL, Neuschwander-Tetri BA, Rinella M, Sanyal AJ. Mechanisms of NAFLD development and therapeutic strategies. Nat Med. 2018 07; 24(7):908-922. PMID: 29967350; PMCID: PMC6553468.
      Citations: 1289     Fields:    Translation:HumansAnimals
    90. Younossi ZM, Loomba R, Anstee QM, Rinella ME, Marchesini G, Neuschwander-Tetri BA, Serfaty L, Negro F, Ratziu V, Corey KE, Friedman SL, Abdelmalek MF, Harrison SA, Sanyal AJ, Mathurin P, Charlton MR, Goodman ZD, Chalasani NP, Kowdley KV, George J, Lindor K, Bugianesi E, Caldwell SH, Lavine JE. Diagnostic modalities for nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and associated fibrosis. Hepatology. 2018 07; 68(1):349-360. PMID: 29222917; PMCID: PMC6511364.
      Citations: 148     Fields:    Translation:Humans
    91. Younossi ZM, Loomba R, Rinella ME, Bugianesi E, Neuschwander-Tetri BA, Serfaty L, Negro F, Caldwell SH, Corey KE, Friedman SL, Abdelmalek MF, Harrison SA, Sanyal AJ, Lavine JE, Charlton MR, Chalasani NP, Anstee QM, Kowdley KV, George J, Goodman ZD, Lindor K, Marchesini G, Ratziu V, Mathurin P. Current and future therapeutic regimens for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Hepatology. 2018 07; 68(1):361-371. PMID: 29222911; PMCID: PMC6508084.
      Citations: 132     Fields:    Translation:Humans
    92. Charlton M, Levitsky J, Aqel B, O'Grady J, Hemibach J, Rinella M, Fung J, Ghabril M, Thomason R, Burra P, Little EC, Shaked A, Trotter J, Roberts J, Rodriguez-Davalos M, Rela M, Pomfret E, Heyrend C, Gallegos-Orozco J, Berenguer M, Saliba F. International Liver Transplantation Society Consensus Statement on Immunosuppression in Liver Transplant Recipients. Transplantation. 2018 05; 102(5):727-743. PMID: 29485508.
      Citations: 70     Fields:    Translation:Humans
    93. Chalasani N, Vuppalanchi R, Rinella M, Middleton MS, Siddiqui MS, Barritt AS, Kolterman O, Flores O, Alonso C, Iruarrizaga-Lejarreta M, Gil-Redondo R, Sirlin CB, Zemel MB. Randomised clinical trial: a leucine-metformin-sildenafil combination (NS-0200) vs placebo in patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2018 06; 47(12):1639-1651. PMID: 29696666; PMCID: PMC6001629.
      Citations: 18     Fields:    Translation:HumansCTClinical Trials
    94. VanWagner LB, Ning H, Allen NB, Siddique J, Carson AP, Bancks MP, Lewis CE, Carr JJ, Speliotes E, Terrault NA, Rinella ME, Vos MB, Lloyd-Jones DM. Twenty-five-year trajectories of insulin resistance and pancreatic ß-cell response and diabetes risk in nonalcoholic fatty liver disease. Liver Int. 2018 11; 38(11):2069-2081. PMID: 29608255; PMCID: PMC6557126.
      Citations: 6     Fields:    Translation:HumansCells
    95. Lee BP, Mehta N, Platt L, Gurakar A, Rice JP, Lucey MR, Im GY, Therapondos G, Han H, Victor DW, Fix OK, Dinges L, Dronamraju D, Hsu C, Voigt MD, Rinella ME, Maddur H, Eswaran S, Hause J, Foley D, Ghobrial RM, Dodge JL, Li Z, Terrault NA. Outcomes of Early Liver Transplantation for Patients With Severe Alcoholic Hepatitis. Gastroenterology. 2018 08; 155(2):422-430.e1. PMID: 29655837; PMCID: PMC6460480.
      Citations: 93     Fields:    Translation:Humans
    96. Harrison SA, Rinella ME, Abdelmalek MF, Trotter JF, Paredes AH, Arnold HL, Kugelmas M, Bashir MR, Jaros MJ, Ling L, Rossi SJ, DePaoli AM, Loomba R. NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet. 2018 03 24; 391(10126):1174-1185. PMID: 29519502.
      Citations: 175     Fields:    Translation:HumansCTClinical Trials
    97. Charlton M, Rinella M, Patel D, McCague K, Heimbach J, Watt K. Everolimus Is Associated With Less Weight Gain Than Tacrolimus 2 Years After Liver Transplantation: Results of a Randomized Multicenter Study. Transplantation. 2017 12; 101(12):2873-2882. PMID: 28817434; PMCID: PMC5704647.
      Citations: 24     Fields:    Translation:HumansCells
    98. VanWagner LB, Khan SS, Ning H, Siddique J, Lewis CE, Carr JJ, Vos MB, Speliotes E, Terrault NA, Rinella ME, Lloyd-Jones DM, Allen NB. Body mass index trajectories in young adulthood predict non-alcoholic fatty liver disease in middle age: The CARDIA cohort study. Liver Int. 2018 04; 38(4):706-714. PMID: 28963767; PMCID: PMC5867197.
      Citations: 24     Fields:    Translation:Humans
    99. ASGE EndoVators Task Force, Ryou M, McQuaid KR, Thompson CC, Edmundowicz S, Mergener K, Abu Dayyeh B, Apovian C, Burke C, Chand B, Chandraker A, Deas T, Dietz W, Dunkin B, Ernest O, Faigel D, Garber S, Hamdy O, Kaplan L, Kumar N, Kushner R, Larsen MC, Lerner H, Littenberg G, Mantzoros C, Mattar S, Moore R, Rinella M, Rothstein R, Schillinger D, Spring B, Sullivan S, Tice J, Vargo J, Wilson E, Woods K, Zundel N. ASGE EndoVators Summit: Defining the role and value of endoscopic therapies in obesity management. Gastrointest Endosc. 2017 11; 86(5):757-767. PMID: 29031371.
      Citations: 1     Fields:    Translation:Humans
    100. Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, Harrison SA, Brunt EM, Sanyal AJ. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018 01; 67(1):328-357. PMID: 28714183.
      Citations: 2363     Fields:    Translation:HumansPHPublic Health
    101. Singhvi A, Sadowsky HS, Cohen A, Demzik A, VanWagner L, Rinella M, Levitsky J. Resting and Exercise Energy Metabolism After Liver Transplantation for Nonalcoholic Steatohepatitis. Transplant Direct. 2017 08; 3(8):e188. PMID: 28795140; PMCID: PMC5540626.
      Citations: 6     
    102. Palatnik A, Rinella ME. Medical and Obstetric Complications Among Pregnant Women With Liver Cirrhosis. Obstet Gynecol. 2017 06; 129(6):1118-1123. PMID: 28486373.
      Citations: 7     Fields:    Translation:Humans
    103. Stine JG, Rinella ME. Editorial: Age and Non-Invasive Markers of Fibrosis in Patients With Nonalcoholic Fatty Liver Disease: Time to Adjust the Clock? Am J Gastroenterol. 2017 05; 112(5):752-754. PMID: 28469217.
      Citations: 6     Fields:    Translation:Humans
    104. Sarkar M, Wellons M, Cedars MI, VanWagner L, Gunderson EP, Ajmera V, Torchen L, Siscovick D, Carr JJ, Terry JG, Rinella M, Lewis CE, Terrault N. Testosterone Levels in Pre-Menopausal Women are Associated With Nonalcoholic Fatty Liver Disease in Midlife. Am J Gastroenterol. 2017 05; 112(5):755-762. PMID: 28291240; PMCID: PMC5664187.
      Citations: 28     Fields:    Translation:Humans
    105. Prenner S, Rinella ME. Moderate Exercise for Nonalcoholic Fatty Liver Disease. JAMA Intern Med. 2016 08 01; 176(8):1083-4. PMID: 27380587.
      Citations: 4     Fields:    Translation:Humans
    106. Rinella M, Charlton M. The globalization of nonalcoholic fatty liver disease: Prevalence and impact on world health. Hepatology. 2016 07; 64(1):19-22. PMID: 26926530.
      Citations: 92     Fields:    Translation:Humans
    107. VanWagner LB, Rinella ME. Extrahepatic Manifestations of Nonalcoholic Fatty Liver Disease. Curr Hepatol Rep. 2016 Jun; 15(2):75-85. PMID: 27218012; PMCID: PMC4874648.
      Citations: 45     
    108. Corey KE, Rinella ME. Medical and Surgical Treatment Options for Nonalcoholic Steatohepatitis. Dig Dis Sci. 2016 May; 61(5):1387-97. PMID: 26942734; PMCID: PMC4838504.
      Citations: 17     Fields:    Translation:Humans
    109. Rinella ME, Sanyal AJ. Management of NAFLD: a stage-based approach. Nat Rev Gastroenterol Hepatol. 2016 Apr; 13(4):196-205. PMID: 26907882.
      Citations: 154     Fields:    Translation:Humans
    110. Rinella ME. Screening for nonalcoholic fatty liver disease in patients with atherosclerotic coronary disease?--In principle yes, in practice not yet. Hepatology. 2016 Mar; 63(3):688-90. PMID: 26566595.
      Citations: 2     Fields:    Translation:HumansPHPublic Health
    111. Rinella ME, Lominadze Z, Loomba R, Charlton M, Neuschwander-Tetri BA, Caldwell SH, Kowdley K, Harrison SA. Practice patterns in NAFLD and NASH: real life differs from published guidelines. Therap Adv Gastroenterol. 2016 Jan; 9(1):4-12. PMID: 26770262; PMCID: PMC4699276.
      Citations: 33     
    112. Brunt EM, Wong VW, Nobili V, Day CP, Maher JJ, Sirlin CB, Neuschwander-Tetri BA, Rinella ME, Sookoian S, Bugianesi E. Nonalcoholic fatty liver disease. Nat Rev Dis Primers. 2015 12 17; 1:15080. PMID: 27188459.
      Citations: 341     Fields:    Translation:HumansCells
    113. VanWagner LB, Wilcox JE, Colangelo LA, Lloyd-Jones DM, Carr JJ, Lima JA, Lewis CE, Rinella ME, Shah SJ. Association of nonalcoholic fatty liver disease with subclinical myocardial remodeling and dysfunction: A population-based study. Hepatology. 2015 Sep; 62(3):773-83. PMID: 25914296; PMCID: PMC4549239.
      Citations: 115     Fields:    Translation:Humans
    114. Rinella ME. Nonalcoholic fatty liver disease: a systematic review. JAMA. 2015 Jun 09; 313(22):2263-73. PMID: 26057287.
      Citations: 892     Fields:    Translation:Humans
    115. VanWagner LB, Lapin B, Skaro AI, Lloyd-Jones DM, Rinella ME. Impact of renal impairment on cardiovascular disease mortality after liver transplantation for nonalcoholic steatohepatitis cirrhosis. Liver Int. 2015 Dec; 35(12):2575-83. PMID: 25977117; PMCID: PMC5204362.
      Citations: 26     Fields:    Translation:Humans
    116. Noureddin M, Rinella ME. Nonalcoholic Fatty liver disease, diabetes, obesity, and hepatocellular carcinoma. Clin Liver Dis. 2015 May; 19(2):361-79. PMID: 25921668; PMCID: PMC6658171.
      Citations: 83     Fields:    Translation:Humans
    117. Rinella ME. The "dose" of exercise and its effects beyond weight loss. Hepatology. 2015 Apr; 61(4):1115-7. PMID: 25546322.
      Citations: 1     Fields:    Translation:Humans
    118. Rinella ME, Sanyal AJ. NAFLD in 2014: Genetics, diagnostics and therapeutic advances in NAFLD. Nat Rev Gastroenterol Hepatol. 2015 Feb; 12(2):65-6. PMID: 25560844; PMCID: PMC4984668.
      Citations: 28     Fields:    Translation:Humans
    119. Kern E, VanWagner LB, Yang GY, Rinella ME. Liraglutide-induced autoimmune hepatitis. JAMA Intern Med. 2014 Jun; 174(6):984-7. PMID: 24733687; PMCID: PMC4423594.
      Citations: 9     Fields:    Translation:Humans
    120. Rinella ME, Loomba R, Caldwell SH, Kowdley K, Charlton M, Tetri B, Harrison SA. Controversies in the Diagnosis and Management of NAFLD and NASH. Gastroenterol Hepatol (N Y). 2014 Apr; 10(4):219-27. PMID: 24976805; PMCID: PMC4073533.
      Citations: 30     
    121. Kia L, Rinella ME. Interpretation and management of hepatic abnormalities in pregnancy. Clin Gastroenterol Hepatol. 2013 Nov; 11(11):1392-8. PMID: 23707777.
      Citations: 1     Fields:    Translation:Humans
    122. McCarthy EM, Rinella M. Authors' response. J Acad Nutr Diet. 2013 Feb; 113(2):211-2. PMID: 23351622.
      Citations:    Fields:    Translation:Humans
    123. Vanwagner LB, Bhave M, Te HS, Feinglass J, Alvarez L, Rinella ME. Patients transplanted for nonalcoholic steatohepatitis are at increased risk for postoperative cardiovascular events. Hepatology. 2012 Nov; 56(5):1741-50. PMID: 22611040.
      Citations: 73     Fields:    Translation:Humans
    124. Larrain S, Rinella ME. A myriad of pathways to NASH. Clin Liver Dis. 2012 Aug; 16(3):525-48. PMID: 22824479.
      Citations: 18     Fields:    Translation:HumansAnimals
    125. McCarthy EM, Rinella ME. The role of diet and nutrient composition in nonalcoholic Fatty liver disease. J Acad Nutr Diet. 2012 Mar; 112(3):401-9. PMID: 22717200.
      Citations: 56     Fields:    Translation:Humans
    126. Rinella ME. Will the increased prevalence of nonalcoholic steatohepatitis (NASH) in the age of better hepatitis C virus therapy make NASH the deadlier disease? Hepatology. 2011 Oct; 54(4):1118-20. PMID: 21956705.
      Citations: 11     Fields:    Translation:Humans
    127. Rinella ME, Siddiqui MS, Gardikiotes K, Gottstein J, Elias M, Green RM. Dysregulation of the unfolded protein response in db/db mice with diet-induced steatohepatitis. Hepatology. 2011 Nov; 54(5):1600-9. PMID: 21748768; PMCID: PMC3205284.
      Citations: 36     Fields:    Translation:AnimalsCells
    128. Henkel AS, Kavesh MH, Kriss MS, Dewey AM, Rinella ME, Green RM. Hepatic overexpression of abcb11 promotes hypercholesterolemia and obesity in mice. Gastroenterology. 2011 Oct; 141(4):1404-11, 1411.e1-2. PMID: 21726512; PMCID: PMC3186850.
      Citations: 10     Fields:    Translation:AnimalsCells
    129. Van Wagner LB, Koppe SW, Brunt EM, Gottstein J, Gardikiotes K, Green RM, Rinella ME. Pentoxifylline for the treatment of non-alcoholic steatohepatitis: a randomized controlled trial. Ann Hepatol. 2011 Jul-Sep; 10(3):277-86. PMID: 21677329.
      Citations: 64     Fields:    Translation:Humans
    130. Van Wagner LB, Rinella ME. The role of insulin-sensitizing agents in the treatment of nonalcoholic steatohepatitis. Therap Adv Gastroenterol. 2011 Jul; 4(4):249-63. PMID: 21765869; PMCID: PMC3131169.
      Citations: 30     
    131. Pillai AA, Lee VS, Wang E, Rinella ME, Levitsky J. Factors associated with sustained virological response in liver transplant recipients with recurrent hepatitis C. Transplant Proc. 2010 Nov; 42(9):3647-51. PMID: 21094833.
      Citations:    Fields:    Translation:HumansCells
    132. Pillai AA, Rinella ME. Non-alcoholic fatty liver disease: is bariatric surgery the answer? Clin Liver Dis. 2009 Nov; 13(4):689-710. PMID: 19818313.
      Citations: 20     Fields:    Translation:Humans
    133. Rinella ME, Elias MS, Smolak RR, Fu T, Borensztajn J, Green RM. Mechanisms of hepatic steatosis in mice fed a lipogenic methionine choline-deficient diet. J Lipid Res. 2008 May; 49(5):1068-76. PMID: 18227531; PMCID: PMC2311450.
      Citations: 197     Fields:    Translation:Animals
    134. Rinella ME. Pregnancy after liver transplantation. Ann Hepatol. 2006 Jul-Sep; 5(3):212-5. PMID: 17060886.
      Citations: 1     Fields:    Translation:Humans
    135. Rinella ME. Primary biliary cirrhosis. Ann Hepatol. 2006 Jul-Sep; 5(3):198-200. PMID: 17060882.
      Citations:    Fields:    Translation:Humans
    136. Rinella ME, Sanyal A. Intensive management of hepatic failure. Semin Respir Crit Care Med. 2006 Jun; 27(3):241-61. PMID: 16791758.
      Citations: 2     Fields:    Translation:Humans
    137. Nie W, Sweetser S, Rinella M, Green RM. Transcriptional regulation of murine Slc22a1 (Oct1) by peroxisome proliferator agonist receptor-alpha and -gamma. Am J Physiol Gastrointest Liver Physiol. 2005 Feb; 288(2):G207-12. PMID: 15458920.
      Citations: 11     Fields:    Translation:AnimalsCells
    138. Rinella ME, Green RM. The methionine-choline deficient dietary model of steatohepatitis does not exhibit insulin resistance. J Hepatol. 2004 Jan; 40(1):47-51. PMID: 14672613.
      Citations: 178     Fields:    Translation:Animals
    139. Rinella ME, McCarthy R, Thakrar K, Finn JP, Rao SM, Koffron AJ, Abecassis M, Blei AT. Dual-echo, chemical shift gradient-echo magnetic resonance imaging to quantify hepatic steatosis: Implications for living liver donation. Liver Transpl. 2003 Aug; 9(8):851-6. PMID: 12884199.
      Citations: 25     Fields:    Translation:Humans
    140. Rinella ME, Shah D, Vogelzang RL, Flamm SL, Blei AT. Fundal variceal bleeding after correction of portal hypertension in patients with cirrhosis. Gastrointest Endosc. 2003 Jul; 58(1):122-7. PMID: 12838239.
      Citations: 1     Fields:    Translation:Humans
    141. Rinella ME, Abecassis MM. Liver biopsy in living donors. Liver Transpl. 2002 Dec; 8(12):1123-5. PMID: 12474150.
      Citations: 1     Fields:    Translation:Humans
    142. Rinella ME, Alonso E, Rao S, Whitington P, Fryer J, Abecassis M, Superina R, Flamm SL, Blei AT. Body mass index as a predictor of hepatic steatosis in living liver donors. Liver Transpl. 2001 May; 7(5):409-14. PMID: 11349260.
      Citations: 55     Fields:    Translation:Humans
    Rinella's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (404)
    Explore
    _
    Co-Authors (13)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _
    Physical Neighbors
    _